Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
KaloBios’ Partnering Hopes




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: KaloBios’ Partnering Hopes
Released on: March 03, 2009. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
With three clinical programmes currently in need of partnering, KaloBios has a very ambitious year ahead. At the beginning of 2008, Dave Pritchard, CEO, spoke to PharmaTelevision® about KaloBios' plans to raise more money through a corporate round of funding. Now he brings us up to speed on the successful closure of that series, along with Jeanne Jew talks through the company's high expectations for 2009.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Kalobios focusing on monoclonal antibody Therapeutics
Fintan Walton:
Hello and welcome to PharmaVentures business review here in San Francisco. On this show I have David Pritchard who is the CEO of Kalobios and Jeanne Jew who is the Head of Business Development at Kalobios. Welcome to the show.
David W. Pritchard:
Thank you.
Jeanne Y. Jew:
Thank you.
Fintan Walton:
Kalobios is a local company. It's based in South San Francisco just down the road. But it's a company that's been around for a while and it's focused on antibodies, it's specifically as therapeutic agents and David W. Pritchard you've been on the show before and welcome back.
David W. Pritchard:
Thanks, it's good to be here.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Jeanne Y. Jew
Head of Pharmaceutical Business Development
David W. Pritchard ,Chief Executive Officer David W. Pritchard, Chief Executive Officer joined Kalobios with more than 25 years of experience in general management, business development and financial management within the biopharmaceutical industry. Most recently he held the position of CBO at Rinat Neuroscience Corporation, where he managed the negotiations on the acquisition of Rinat, by Pfizer, in 2006 for a reported $500 million. Prior to that he was CFO at Matrix Pharmaceuticals, and managed the sale of the company to Chiron Corporation in 2002, now Novartis. Between 1992 and 2000 David served as VP, Business Development and CFO of Metabolex, Inc. where he completed three rounds of financing and negotiated four worldwide corporate alliances with major pharmaceutical companies, and in-licensed metaglidasen. He started his biotechnology career at Triton Biosciences, Inc. As one of the founding managers, where he held various positions including heading up the sales and marketing efforts, commercial development, a business unit, and ultimately managed the sale of Triton predominately to Schering AG, now Bayer. Triton developed Betaseron for multiple sclerosis(2005 sales exceeded $1 billion), and Fludara for leukemia. David holds an MBA degree from Stanford University, and a BS in Chemical Engineering from Cornell. Jeanne Y. Jew, Head of Pharmaceutical Business Development Ms. Jeanne Y. Jew, Head of Pharmaceutical Business Development, joined Kalobios with over 15 years of experience in business development in the biopharmaceutical industry. Previously Ms. Jeanne Y. Jew served as Vice President, Corporate and Commercial Development at Onyx Pharmaceuticals, Inc. From 2002 to 2007 where she was responsible for all business development activities. Prior to Onyx Pharmaceuticals, Ms. Jeanne Y. Jew served in positions of increasing responsibility at Coulter Pharmaceutical and became Vice President, Business Development following the acquisition of Coulter Pharmaceutical by Corixa Corporation. Ms. Jeanne Y. Jew has also held business development positions at Scios, Inc and Genentech, Inc. Ms. Jeanne Y. Jew holds a BA in Psychology from Wesleyan University and a MBA in Business Administration from Cornell University.
Kalobios
Kalobios Pharmaceuticals, Inc., a U.S based, private monoclonal company, uses it's proprietary platform technology to develop first or best-in-class human antibody therapeutics. The company's proprietary Humaneering technology offers advantages over other methods of human antibody creation in terms of immunogenicity, potency, and manufacturing yields. The company focuses on partnering it's clinical-stage programs and also grants limited access to it's Humaneering platform to select partners. Kalobios was formed in 2001 and merged in 2004 with Celscia. Since the company's founding, it has raised a total of $68 million in four rounds of venture funding with the major shareholders being MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Venture Partners, Mitsubishi UFJ Capital and Genzyme Ventures. The company is headquartered in South San Francisco, CA and has approximately 50 employees.